Mycophenolic Acid Formulations in Adult Renal Transplantation - Update on Efficacy and Tolerability

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2009 Sep 16

PMID 19753127

Citations 3

Authors

Dela Golshayan

M Pascual

Bruno Vogt

Affiliations

Soon will be listed here.

Abstract

The description more than 30 years ago of the role of de novo purine synthesis in T and B lymphocytes clonal proliferation opened the possibility for selective immunosuppression by targeting specific enzymatic pathways. Mycophenolic acid (MPA) blocks the key enzyme inosine monophosphate dehydrogenase and the production of guanosine nucleotides required for DNA synthesis. Two MPA formulations are currently used in clinical transplantation as part of the maintenance immunosuppressive regimen. Mycophenolate mofetil (MMF) was the first MPA agent to be approved for the prevention of acute rejection following renal transplantation, in combination with cyclosporine and steroids. Enteric-coated mycophenolate sodium (EC-MPS) is an alternative MPA formulation available in clinical transplantation. In this review, we will discuss the clinical trials that have evaluated the efficacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy. We will also discuss MPA pharmacokinetics and the rationale for therapeutic drug monitoring in optimizing the balance between efficacy and safety in individual patients.

Citing Articles

Overview of fungal terpene synthases and their regulation.

Gonzalez-Hernandez R, Valdez-Cruz N, Macias-Rubalcava M, Trujillo-Roldan M World J Microbiol Biotechnol. 2023; 39(7):194.

PMID: 37169980 PMC: 10175467. DOI: 10.1007/s11274-023-03635-y.

Reviewing the recommendations for lupus in children.

Arici Z, Batu E, Ozen S Curr Rheumatol Rep. 2015; 17(3):17.

PMID: 25761924 DOI: 10.1007/s11926-014-0489-5.

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden J Ann Rheum Dis. 2012; 71(11):1771-82.

PMID: 22851469 PMC: 3465859. DOI: 10.1136/annrheumdis-2012-201940.

References

Abramowicz D, Del Carmen Rial M, Vitko S, Del Castillo D, Manas D, Lao M . Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16(7):2234-40. DOI: 10.1681/ASN.2004100844. View

Premaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y . A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005; 44(8):837-47. DOI: 10.2165/00003088-200544080-00005. View

Johnston A, He X, Holt D . Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006; 82(11):1413-8. DOI: 10.1097/01.tp.0000242137.68863.89. View

Kreis H, Cisterne J, Land W, Wramner L, Squifflet J, Abramowicz D . Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000; 69(7):1252-60. DOI: 10.1097/00007890-200004150-00009. View

Willis C, Taylor P, Salm P, Tett S, Pillans P . Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000; 22(5):549-54. DOI: 10.1097/00007691-200010000-00008. View

Larson T, Dean P, Stegall M, Griffin M, Textor S, Schwab T . Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006; 6(3):514-22. DOI: 10.1111/j.1600-6143.2005.01177.x. View

Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G . Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007; 18(6):1973-85. DOI: 10.1681/ASN.2006101153. View

Grinyo J, Gil-Vernet S, Cruzado J, Caldes A, Riera L, Seron D . Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int. 2003; 16(11):820-7. DOI: 10.1007/s00147-003-0638-7. View

Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C . Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997; 63(1):39-47. DOI: 10.1097/00007890-199701150-00008. View

10.

. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996; 61(7):1029-37. View

11.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

12.

Golshayan D, Pascual M . Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl Immunol. 2008; 20(1-2):21-8. DOI: 10.1016/j.trim.2008.08.006. View

13.

Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A . Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007; 7(3):560-70. DOI: 10.1111/j.1600-6143.2006.01645.x. View

14.

Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov B, Ene-Iordache B . Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet. 2004; 364(9433):503-12. DOI: 10.1016/S0140-6736(04)16808-6. View

15.

. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation. 2001; 71(8):1091-7. DOI: 10.1097/00007890-200104270-00014. View

16.

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

17.

Salvadori M, Holzer H, Civati G, Sollinger H, Lien B, Tomlanovich S . Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol. 2006; 66(2):112-9. View

18.

Nowak I, Shaw L . Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995; 41(7):1011-7. View

19.

Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V . Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005; 19(2):199-206. DOI: 10.1111/j.1399-0012.2004.00318.x. View

20.

Sintchak M, Fleming M, Futer O, Raybuck S, Chambers S, Caron P . Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 1996; 85(6):921-30. DOI: 10.1016/s0092-8674(00)81275-1. View